<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147143</url>
  </required_header>
  <id_info>
    <org_study_id>CaboCHECK</org_study_id>
    <nct_id>NCT04147143</nct_id>
  </id_info>
  <brief_title>CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study</brief_title>
  <official_title>Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional study to retrospectively evaluate the safety and to describe the&#xD;
      effectiveness of cabozantinib after immunoncologic treatment with nivolumab or nivolumab plus&#xD;
      ipilimumab in routine clinical practice. It consists of a retrospective chart review of&#xD;
      patients who have already completed treatment with cabozantinib after nivolumab or nivolumab&#xD;
      plus ipilimumab before inclusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Incidence of serious adverse events at least possibly related to cabozantinib treatment during and up to 30 days after the end of cabozantinib treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of dose reductions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of dose reductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of dose interruptions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of dose interruptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of terminations of cabozantinib treatment due to adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>number of terminations of cabozantinib treatment due to adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ORR (investigator assessed; acc. RECIST v1.1 if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Clinical benefit rate (CBR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Duration of response in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of cabozantinib treatment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Duration of cabozantinib treatment in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>From date of last dose of cabozantinib until the date of first dose of next treatment, assessed up to 100 months</time_frame>
    <description>Time to next treatment in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety in IO-cabozantinib-sequence compared to cabozantinib single agent therapy historical data</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety in IO-cabozantinib-sequence compared to cabozantinib single agent therapy historical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of effectiveness endpoints of IO-cabozantinib-sequence to historical efficacy data (ORR, CBR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Comparison of effectiveness endpoints of IO-cabozantinib-sequence to historical efficacy data (ORR, CBR)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced Renal Cell Carcinoma (All Subtypes)</condition>
  <condition>Metastatic Renal Cell Carcinoma (All Subtypes)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Documentation</intervention_name>
    <description>Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults ≥ 18 years with advanced or metastatic renal cell carcinoma (all subtypes) who have&#xD;
        completed treatment with nivolumab or nivolumab plus ipilimumab (any line of systemic&#xD;
        therapy) directly followed by cabozantinib treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent and any locally-required authorization (EU Data Privacy&#xD;
             Directive in the EU) obtained from the subject&#xD;
&#xD;
          2. Patients with advanced or metastatic renal cell carcinoma, including all subtypes&#xD;
&#xD;
          3. Age ≥ 18 years&#xD;
&#xD;
          4. Completion of treatment with nivolumab or nivolumab / ipilimumab combination therapy&#xD;
             (any line of therapy) directly followed by cabozantinib treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are unable to consent because they do not understand the nature,&#xD;
             significance and implications of the observational trial&#xD;
&#xD;
          2. Involvement in the planning and / or conduct of the study (applies to both Ipsen staff&#xD;
             and/or staff of sponsor and study site)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viktor Grünwald, Prof. Dr.</last_name>
    <phone>+49201723</phone>
    <phone_ext>3214</phone_ext>
    <email>viktor.gruenwald@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Schönherr, Dr.</last_name>
    <phone>+49 (0)697601</phone>
    <phone_ext>4094</phone_ext>
    <email>schoenherr.caroline@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktor Grünwald, Prof. Dr.</last_name>
      <phone>+49 201723-</phone>
      <phone_ext>3214</phone_ext>
      <email>viktor.gruenwald@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bögemann, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

